Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients
Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors iden...
Gespeichert in:
| Veröffentlicht in: | Clinical lung cancer 2019-07, Vol.20 (4), p.305-312.e3 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 312.e3 |
|---|---|
| container_issue | 4 |
| container_start_page | 305 |
| container_title | Clinical lung cancer |
| container_volume | 20 |
| creator | Mezquita, Laura Benito, Amparo Ruano-Raviña, Alberto Zamora, Javier Olmedo, Maria Eugenia Reguera, Pablo Madariaga, Ainhoa Villamayor, María Cortez, Silvia Patricia Gorospe, Luis Santón, Almudena Mayoralas, Sagrario Hernanz, Raúl Cabañero, Alberto Auclin, Edouard Carrato, Alfredo Garrido, Pilar |
| description | Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations.
We assessed the radon concentration from EGFR-, BRAF-mutated (m), and ALK-rearranged (r) NSCLC patients measured by an alpha-track detector placed in their homes between September 2014 and August 2015. Clinical characteristics were collected prospectively, and pathologic samples were reviewed retrospectively.
Forty-eight patients were included (36 EGFRm, 10 ALKr, 2 BRAFm). Median radon concentration was 104 Bq/m³ (IQR 69-160) overall, and was 96 Bq/m³ (42-915) for EGFRm, 116 (64-852) for ALKr, and 125 for BRAFm, with no significant differences. Twenty-seven patients (56%) had indoor radon above WHO recommendations, 8 (80%) of 10 ALKr, 2 (100%) of 2 BRAFm, and 17 (47%) of 36 EGFRm.
The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies.
Radon is the first cause of lung cancer in nonsmokers according to the World Health Organization (WHO), which recommends not exceeding 100Bq/m³ in homes. No risk factor has yet been identified for non–small-cell lung cancer (NSCLC) harboring driver alterations, mainly nonsmokers. We found a median concentration of 104 Bq/m³, above the WHO recommendation in EGFR-mutated, BRAF-mutated, and ALK-rearranged NSCLC patients, with no differences between them. |
| doi_str_mv | 10.1016/j.cllc.2019.04.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2233857088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525730419301007</els_id><sourcerecordid>2233857088</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-bbdc36b2fd2bff46bb58f026320273ca0581b666de6bc894fe9a240213b02e7f3</originalsourceid><addsrcrecordid>eNp9kM1O3DAUhS1ExV95ARYoSzYO13biJBKbYcQA6vRH03Zt-ecGZZRxwE6Q2PUd-oZ9kno6lCWre3V1ztG5HyFnDHIGTF6uc9v3NufAmhyKHKDZI0esETUF2cB-2kte0kpAcUiOY1wDcCkYPyCHgrGSVTU_Iureu2EI2Uq7wWedz25uFyuaae-y69VsQT9Pox7R_TvMlp_oCnUI2j-k05fB__n1-_tG9z2dY99ny8k_ZHPtLYbsmx479GP8SD60uo94-jpPyM_FzY_5HV1-vb2fz5bUilKO1BhnhTS8ddy0bSGNKet2W5cDr4TVUNbMSCkdSmPrpmix0bwAzoQBjlUrTsjFLvcxDE8TxlFtumhTK-1xmKLiXIi6rKCuk5TvpDYMMQZs1WPoNjq8KAZqC1at1Ras2oJVUKgENpnOX_Mns0H3ZvlPMgmudgJMXz53GFS0iYBF1wW0o3JD917-X-XjiEo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2233857088</pqid></control><display><type>article</type><title>Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Mezquita, Laura ; Benito, Amparo ; Ruano-Raviña, Alberto ; Zamora, Javier ; Olmedo, Maria Eugenia ; Reguera, Pablo ; Madariaga, Ainhoa ; Villamayor, María ; Cortez, Silvia Patricia ; Gorospe, Luis ; Santón, Almudena ; Mayoralas, Sagrario ; Hernanz, Raúl ; Cabañero, Alberto ; Auclin, Edouard ; Carrato, Alfredo ; Garrido, Pilar</creator><creatorcontrib>Mezquita, Laura ; Benito, Amparo ; Ruano-Raviña, Alberto ; Zamora, Javier ; Olmedo, Maria Eugenia ; Reguera, Pablo ; Madariaga, Ainhoa ; Villamayor, María ; Cortez, Silvia Patricia ; Gorospe, Luis ; Santón, Almudena ; Mayoralas, Sagrario ; Hernanz, Raúl ; Cabañero, Alberto ; Auclin, Edouard ; Carrato, Alfredo ; Garrido, Pilar</creatorcontrib><description>Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations.
We assessed the radon concentration from EGFR-, BRAF-mutated (m), and ALK-rearranged (r) NSCLC patients measured by an alpha-track detector placed in their homes between September 2014 and August 2015. Clinical characteristics were collected prospectively, and pathologic samples were reviewed retrospectively.
Forty-eight patients were included (36 EGFRm, 10 ALKr, 2 BRAFm). Median radon concentration was 104 Bq/m³ (IQR 69-160) overall, and was 96 Bq/m³ (42-915) for EGFRm, 116 (64-852) for ALKr, and 125 for BRAFm, with no significant differences. Twenty-seven patients (56%) had indoor radon above WHO recommendations, 8 (80%) of 10 ALKr, 2 (100%) of 2 BRAFm, and 17 (47%) of 36 EGFRm.
The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies.
Radon is the first cause of lung cancer in nonsmokers according to the World Health Organization (WHO), which recommends not exceeding 100Bq/m³ in homes. No risk factor has yet been identified for non–small-cell lung cancer (NSCLC) harboring driver alterations, mainly nonsmokers. We found a median concentration of 104 Bq/m³, above the WHO recommendation in EGFR-mutated, BRAF-mutated, and ALK-rearranged NSCLC patients, with no differences between them.</description><identifier>ISSN: 1525-7304</identifier><identifier>EISSN: 1938-0690</identifier><identifier>DOI: 10.1016/j.cllc.2019.04.009</identifier><identifier>PMID: 31151782</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Air Pollution, Indoor - adverse effects ; Anaplastic Lymphoma Kinase - genetics ; Carcinoma, Non-Small-Cell Lung - genetics ; Driver oncogene ; ErbB Receptors - genetics ; Female ; Gene Rearrangement ; Humans ; Lung Neoplasms - genetics ; Male ; Middle Aged ; Mutation - genetics ; NSCLC ; Prospective Studies ; Proto-Oncogene Proteins B-raf - genetics ; Radioactivity ; Radon - adverse effects ; Radon gas ; Retrospective Studies</subject><ispartof>Clinical lung cancer, 2019-07, Vol.20 (4), p.305-312.e3</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-bbdc36b2fd2bff46bb58f026320273ca0581b666de6bc894fe9a240213b02e7f3</citedby><cites>FETCH-LOGICAL-c356t-bbdc36b2fd2bff46bb58f026320273ca0581b666de6bc894fe9a240213b02e7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1525730419301007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31151782$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mezquita, Laura</creatorcontrib><creatorcontrib>Benito, Amparo</creatorcontrib><creatorcontrib>Ruano-Raviña, Alberto</creatorcontrib><creatorcontrib>Zamora, Javier</creatorcontrib><creatorcontrib>Olmedo, Maria Eugenia</creatorcontrib><creatorcontrib>Reguera, Pablo</creatorcontrib><creatorcontrib>Madariaga, Ainhoa</creatorcontrib><creatorcontrib>Villamayor, María</creatorcontrib><creatorcontrib>Cortez, Silvia Patricia</creatorcontrib><creatorcontrib>Gorospe, Luis</creatorcontrib><creatorcontrib>Santón, Almudena</creatorcontrib><creatorcontrib>Mayoralas, Sagrario</creatorcontrib><creatorcontrib>Hernanz, Raúl</creatorcontrib><creatorcontrib>Cabañero, Alberto</creatorcontrib><creatorcontrib>Auclin, Edouard</creatorcontrib><creatorcontrib>Carrato, Alfredo</creatorcontrib><creatorcontrib>Garrido, Pilar</creatorcontrib><title>Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients</title><title>Clinical lung cancer</title><addtitle>Clin Lung Cancer</addtitle><description>Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations.
We assessed the radon concentration from EGFR-, BRAF-mutated (m), and ALK-rearranged (r) NSCLC patients measured by an alpha-track detector placed in their homes between September 2014 and August 2015. Clinical characteristics were collected prospectively, and pathologic samples were reviewed retrospectively.
Forty-eight patients were included (36 EGFRm, 10 ALKr, 2 BRAFm). Median radon concentration was 104 Bq/m³ (IQR 69-160) overall, and was 96 Bq/m³ (42-915) for EGFRm, 116 (64-852) for ALKr, and 125 for BRAFm, with no significant differences. Twenty-seven patients (56%) had indoor radon above WHO recommendations, 8 (80%) of 10 ALKr, 2 (100%) of 2 BRAFm, and 17 (47%) of 36 EGFRm.
The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies.
Radon is the first cause of lung cancer in nonsmokers according to the World Health Organization (WHO), which recommends not exceeding 100Bq/m³ in homes. No risk factor has yet been identified for non–small-cell lung cancer (NSCLC) harboring driver alterations, mainly nonsmokers. We found a median concentration of 104 Bq/m³, above the WHO recommendation in EGFR-mutated, BRAF-mutated, and ALK-rearranged NSCLC patients, with no differences between them.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Air Pollution, Indoor - adverse effects</subject><subject>Anaplastic Lymphoma Kinase - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Driver oncogene</subject><subject>ErbB Receptors - genetics</subject><subject>Female</subject><subject>Gene Rearrangement</subject><subject>Humans</subject><subject>Lung Neoplasms - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation - genetics</subject><subject>NSCLC</subject><subject>Prospective Studies</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Radioactivity</subject><subject>Radon - adverse effects</subject><subject>Radon gas</subject><subject>Retrospective Studies</subject><issn>1525-7304</issn><issn>1938-0690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1O3DAUhS1ExV95ARYoSzYO13biJBKbYcQA6vRH03Zt-ecGZZRxwE6Q2PUd-oZ9kno6lCWre3V1ztG5HyFnDHIGTF6uc9v3NufAmhyKHKDZI0esETUF2cB-2kte0kpAcUiOY1wDcCkYPyCHgrGSVTU_Iureu2EI2Uq7wWedz25uFyuaae-y69VsQT9Pox7R_TvMlp_oCnUI2j-k05fB__n1-_tG9z2dY99ny8k_ZHPtLYbsmx479GP8SD60uo94-jpPyM_FzY_5HV1-vb2fz5bUilKO1BhnhTS8ddy0bSGNKet2W5cDr4TVUNbMSCkdSmPrpmix0bwAzoQBjlUrTsjFLvcxDE8TxlFtumhTK-1xmKLiXIi6rKCuk5TvpDYMMQZs1WPoNjq8KAZqC1at1Ras2oJVUKgENpnOX_Mns0H3ZvlPMgmudgJMXz53GFS0iYBF1wW0o3JD917-X-XjiEo</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Mezquita, Laura</creator><creator>Benito, Amparo</creator><creator>Ruano-Raviña, Alberto</creator><creator>Zamora, Javier</creator><creator>Olmedo, Maria Eugenia</creator><creator>Reguera, Pablo</creator><creator>Madariaga, Ainhoa</creator><creator>Villamayor, María</creator><creator>Cortez, Silvia Patricia</creator><creator>Gorospe, Luis</creator><creator>Santón, Almudena</creator><creator>Mayoralas, Sagrario</creator><creator>Hernanz, Raúl</creator><creator>Cabañero, Alberto</creator><creator>Auclin, Edouard</creator><creator>Carrato, Alfredo</creator><creator>Garrido, Pilar</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201907</creationdate><title>Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients</title><author>Mezquita, Laura ; Benito, Amparo ; Ruano-Raviña, Alberto ; Zamora, Javier ; Olmedo, Maria Eugenia ; Reguera, Pablo ; Madariaga, Ainhoa ; Villamayor, María ; Cortez, Silvia Patricia ; Gorospe, Luis ; Santón, Almudena ; Mayoralas, Sagrario ; Hernanz, Raúl ; Cabañero, Alberto ; Auclin, Edouard ; Carrato, Alfredo ; Garrido, Pilar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-bbdc36b2fd2bff46bb58f026320273ca0581b666de6bc894fe9a240213b02e7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Air Pollution, Indoor - adverse effects</topic><topic>Anaplastic Lymphoma Kinase - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Driver oncogene</topic><topic>ErbB Receptors - genetics</topic><topic>Female</topic><topic>Gene Rearrangement</topic><topic>Humans</topic><topic>Lung Neoplasms - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation - genetics</topic><topic>NSCLC</topic><topic>Prospective Studies</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Radioactivity</topic><topic>Radon - adverse effects</topic><topic>Radon gas</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mezquita, Laura</creatorcontrib><creatorcontrib>Benito, Amparo</creatorcontrib><creatorcontrib>Ruano-Raviña, Alberto</creatorcontrib><creatorcontrib>Zamora, Javier</creatorcontrib><creatorcontrib>Olmedo, Maria Eugenia</creatorcontrib><creatorcontrib>Reguera, Pablo</creatorcontrib><creatorcontrib>Madariaga, Ainhoa</creatorcontrib><creatorcontrib>Villamayor, María</creatorcontrib><creatorcontrib>Cortez, Silvia Patricia</creatorcontrib><creatorcontrib>Gorospe, Luis</creatorcontrib><creatorcontrib>Santón, Almudena</creatorcontrib><creatorcontrib>Mayoralas, Sagrario</creatorcontrib><creatorcontrib>Hernanz, Raúl</creatorcontrib><creatorcontrib>Cabañero, Alberto</creatorcontrib><creatorcontrib>Auclin, Edouard</creatorcontrib><creatorcontrib>Carrato, Alfredo</creatorcontrib><creatorcontrib>Garrido, Pilar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lung cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mezquita, Laura</au><au>Benito, Amparo</au><au>Ruano-Raviña, Alberto</au><au>Zamora, Javier</au><au>Olmedo, Maria Eugenia</au><au>Reguera, Pablo</au><au>Madariaga, Ainhoa</au><au>Villamayor, María</au><au>Cortez, Silvia Patricia</au><au>Gorospe, Luis</au><au>Santón, Almudena</au><au>Mayoralas, Sagrario</au><au>Hernanz, Raúl</au><au>Cabañero, Alberto</au><au>Auclin, Edouard</au><au>Carrato, Alfredo</au><au>Garrido, Pilar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients</atitle><jtitle>Clinical lung cancer</jtitle><addtitle>Clin Lung Cancer</addtitle><date>2019-07</date><risdate>2019</risdate><volume>20</volume><issue>4</issue><spage>305</spage><epage>312.e3</epage><pages>305-312.e3</pages><issn>1525-7304</issn><eissn>1938-0690</eissn><abstract>Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations.
We assessed the radon concentration from EGFR-, BRAF-mutated (m), and ALK-rearranged (r) NSCLC patients measured by an alpha-track detector placed in their homes between September 2014 and August 2015. Clinical characteristics were collected prospectively, and pathologic samples were reviewed retrospectively.
Forty-eight patients were included (36 EGFRm, 10 ALKr, 2 BRAFm). Median radon concentration was 104 Bq/m³ (IQR 69-160) overall, and was 96 Bq/m³ (42-915) for EGFRm, 116 (64-852) for ALKr, and 125 for BRAFm, with no significant differences. Twenty-seven patients (56%) had indoor radon above WHO recommendations, 8 (80%) of 10 ALKr, 2 (100%) of 2 BRAFm, and 17 (47%) of 36 EGFRm.
The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies.
Radon is the first cause of lung cancer in nonsmokers according to the World Health Organization (WHO), which recommends not exceeding 100Bq/m³ in homes. No risk factor has yet been identified for non–small-cell lung cancer (NSCLC) harboring driver alterations, mainly nonsmokers. We found a median concentration of 104 Bq/m³, above the WHO recommendation in EGFR-mutated, BRAF-mutated, and ALK-rearranged NSCLC patients, with no differences between them.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31151782</pmid><doi>10.1016/j.cllc.2019.04.009</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-7304 |
| ispartof | Clinical lung cancer, 2019-07, Vol.20 (4), p.305-312.e3 |
| issn | 1525-7304 1938-0690 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2233857088 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Aged, 80 and over Air Pollution, Indoor - adverse effects Anaplastic Lymphoma Kinase - genetics Carcinoma, Non-Small-Cell Lung - genetics Driver oncogene ErbB Receptors - genetics Female Gene Rearrangement Humans Lung Neoplasms - genetics Male Middle Aged Mutation - genetics NSCLC Prospective Studies Proto-Oncogene Proteins B-raf - genetics Radioactivity Radon - adverse effects Radon gas Retrospective Studies |
| title | Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T22%3A57%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Indoor%20Radon%20in%20EGFR-%20and%20BRAF-Mutated%20and%20ALK-Rearranged%20Non%E2%80%93Small-Cell%20Lung%20Cancer%20Patients&rft.jtitle=Clinical%20lung%20cancer&rft.au=Mezquita,%20Laura&rft.date=2019-07&rft.volume=20&rft.issue=4&rft.spage=305&rft.epage=312.e3&rft.pages=305-312.e3&rft.issn=1525-7304&rft.eissn=1938-0690&rft_id=info:doi/10.1016/j.cllc.2019.04.009&rft_dat=%3Cproquest_cross%3E2233857088%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2233857088&rft_id=info:pmid/31151782&rft_els_id=S1525730419301007&rfr_iscdi=true |